Gil Van Bokkelen's guest appearances

Gil Van Bokkelen

Empowered Patient Podcast

ForbesBooks Radio

Hand in Hand

David Katz

Rosalind Picard

David Solomon

Matt Murphy

Robin Smith

Thomas Cowan

Greg Miller

Travis Mickle

Justin Miller

Sean Tucker

Matt Wilson

Chris Young

Jim Martin

Robin Zander

Andrew Newberg

OwlTail

Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform.  Gil explains how cell therapies work by providing multi-dimensional solutions and how regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing.  He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers. @Athersys #regenerativemedicine #ARDS Athersys.com Download the transcript here

Dr. Gil Van Bokkelen, founder and CEO, Athersys a clinical stage biotech company, talks about developing cell therapies and regenerative medicine as alternatives to conventional standards of medical intervention and treatment using their MultiStem cell therapy platform.  Gil explains how cell therapies work by providing multi-dimensional solutions and how regenerative medicine therapies differ from traditional pharmaceuticals or biologics designed to do one very specific thing.  He also talks about how MultiStem has shown dramatic impact on stroke victims and on acute respiratory distress syndrome and inflammation in the lungs and their related work with lung transplant centers. @Athersys #regenerativemedicine #ARDS <a href="http://athersys.com" rel="noopener nofollow" target="_blank">Athersys.com</a> <a href="http://empoweredpatientradio.com/cell-therapy-and-regenerative-medicine-advances-with-dr-gil-van-bokkelen-athersys-transcript" rel="noopener nofollow" target="_blank">Download the transcript here</a>

Cell Therapy and Regenerative Medicine Advances with Dr. Gil Van Bokkelen Athersys

Multistem®, a drug-like cell therapy to treat stroke with adult stem cells is developed by Athersys (ATH-er-sis), a clinical-stage biotechnology company founded by a group of leading scientists in 1995. In Episode 91, we interviewed Sharon Thomas, a survivor who experienced miraculous recovery after given multistem.Athersys is conducting the Phase 3 clinical trials for MultiStem®. During Phase 2 trials in the U.S, the studies showed that MultiStem® could extend the treatment window for ischemic stroke patients to 36 hours, compared to the 3 or 4 hour window to treat patients with TPA. That meant individuals who may have had a stroke in their sleep, or patients who did not recognize the symptoms right away, might still have a favorable outcome with MultiStem® versus TPA.Multistem® has obtained FDA’s Fast Track designation. It is also in Phase 3 studies in Japan. Our guest today is Gil Van Bokkelen, CEO of Athersys, who will share with us exciting progress of Multistem®.

Multistem®, a drug-like cell therapy to treat stroke with adult stem cells is developed by Athersys (ATH-er-sis), a clinical-stage biotechnology company founded by a group of leading scientists in 1995. In Episode 91, we interviewed Sharon Thomas, a survivor who experienced miraculous recovery after given multistem. Athersys is conducting the Phase 3 clinical trials for MultiStem®. During Phase 2 trials in the U.S, the studies showed that MultiStem® could extend the treatment window for ischemic stroke patients to 36 hours, compared to the 3 or 4 hour window to treat patients with TPA. That meant individuals who may have had a stroke in their sleep, or patients who did not recognize the symptoms right away, might still have a favorable outcome with MultiStem® versus TPA. Multistem® has obtained FDA’s Fast Track designation. It is also in Phase 3 studies in Japan. Our guest today is Gil Van Bokkelen, CEO of Athersys, who will share with us exciting progress of Multistem®.

Episode 93 Multistem A Game Changer - Interview With Gil Van Bokkelen, CEO of Athersys